Nicole M Iovine, MD, PhD
Program Director; Clinical Professor & Hospital Epidemiologist
Department:
MD-INFECTIOUS DISEASES
Business Phone:
(352) 273-8606
Business Email:
nicole.iovine@medicine.ufl.edu
About Nicole M Iovine
Additional Positions:
Section Chief, Epidemiology and Antimicrobial Stewardship
2018 – Current
·
University of Florida
Accomplishments
Fellow of the Infectious Disease Society of America
2017
·
Infectious Disease Society of America
Outstanding Leadership in Quality and Patient Safety
2014
·
University of Florida Health
Excellence in Teaching Award
2012
·
University of Florida
Special Citation of Excellence for a Poster Presentation
2005
·
43rd Annual Meeting of the IDSA
Infectious Disease Fellow of the Year
2002
·
New York University
Alpha Omega Alpha Honor Society
2000
·
New York University School of Medicine
Golden Key National Honor Society
1992
·
City University of New York
Valedictorian
1992
·
City University of New York
Teaching Profile
Courses Taught
2018
MDT7200 Elect Top/Medicine
2018,2024-2025
BMS6300 Fund Micro and Immuno
Board Certifications
-
Infectious DiseaseAmerican Board of Internal Medicine
-
Internal MedicineAmerican Board of Internal Medicine
Clinical Profile
Specialties
- Infectious Disease
Areas of Interest
- Avian Influenza
- Coronavirus Disease 2019 (COVID-19)
- Infectious diseases
Research Profile
I am trained as both an Infectious Disease specialist and as an expert in innate defense against bacterial infection, with a focus on Gram-negative organisms. As an Infectious Disease specialist, I am particularly interested in treatment approaches to multidrug-resistant Gram-negative infections. As a researcher, I study the innate defenses against these types of infections. In one project, I study the Bactericidal/Permeability-Increasing protein (BPI) – an endogenous antibiotic found in neutrophils and available in recombinant form. BPI has potent activity against Gram-negative bacteria, including multidrug-resistant clinical isolates I collect.
I have also studied emerging infections, such as chikungunya, Zika and seasonal influenza. I was engaged in two NIH-sponsored clinical trials for the treatment of seasonal influenza with immune plasma and triple therapy (ribivirin, oseltamivir and amantadine). I was the Principal Investigator for UF site of the NIH-sponsored Adaptive COVID-19 Treatment Trials (ACTT), which identified remdesivir and baricitinib as important agents for the treatment of COVID patients. Most recently, I am the Principal Investigator for the UF site of the STOMP monkeypox clinical trial, and for the Accelerating COVID-19 Therapeutic Interventions and Vaccines clinical trials (ACTIV4a and ACTIV4d).
Open Researcher and Contributor ID (ORCID)
0000-0002-5032-6485
Publications
Academic Articles
2025
Shock prediction with dipeptidyl peptidase-3 and renin (SPiDeR) in hypoxemic patients with COVID-19.
Journal of critical care.
85
[DOI] 10.1016/j.jcrc.2024.154950.
[PMID] 39546997.
2024
Brincidofovir for disease progression due to suspected tecovirimat resistance in association with advanced HIV.
International journal of STD & AIDS.
35(8):651-653
[DOI] 10.1177/09564624241238813.
[PMID] 38502040.
2024
Fostamatinib for Hospitalized Adults With COVID-19 and Hypoxemia: A Randomized Clinical Trial.
JAMA network open.
7(12)
[DOI] 10.1001/jamanetworkopen.2024.48215.
[PMID] 39625722.
2024
Trends in the appropriateness of oral antibiotic prescriptions dispensed in the United States from 2010 to 2018.
Pharmacotherapy.
44(9):701-710
[DOI] 10.1002/phar.4604.
[PMID] 39239761.
2023
Effect of P2Y12 Inhibitors on Organ Support-Free Survival in Critically Ill Patients Hospitalized for COVID-19: A Randomized Clinical Trial.
JAMA network open.
6(5)
[DOI] 10.1001/jamanetworkopen.2023.14428.
[PMID] 37227729.
2023
Evaluating Demographic Representation in Clinical Trials: Use of the Adaptive Coronavirus Disease 2019 Treatment Trial (ACTT) as a Test Case.
Open forum infectious diseases.
10(6)
[DOI] 10.1093/ofid/ofad290.
[PMID] 37383244.
2023
Oral fluoroquinolones and risk of aortic aneurysm or dissection: A nationwide population-based propensity score-matched cohort study.
Pharmacotherapy.
43(9):883-893
[DOI] 10.1002/phar.2841.
[PMID] 37381584.
2023
Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor-Biased Ligand in Adults With COVID-19: Two Randomized Clinical Trials.
JAMA.
329(14):1170-1182
[DOI] 10.1001/jama.2023.3546.
[PMID] 37039791.
2023
Seafood-Associated Outbreak of ctx-Negative Vibrio mimicus Causing Cholera-Like Illness, Florida, USA.
Emerging infectious diseases.
29(10):2141-2144
[DOI] 10.3201/eid2910.230486.
[PMID] 37735754.
2023
Use of therapeutic drug monitoring to characterize cefepime-related neurotoxicity.
Pharmacotherapy.
43(1):6-14
[DOI] 10.1002/phar.2744.
[PMID] 36401796.
2022
Association between lipid profiles and viral respiratory infections in human sputum samples.
Respiratory research.
23(1)
[DOI] 10.1186/s12931-022-02091-w.
[PMID] 35780155.
2022
Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial.
The Lancet. Respiratory medicine.
10(9):888-899
[DOI] 10.1016/S2213-2600(22)00088-1.
[PMID] 35617986.
2022
Isolation of a Novel Recombinant Canine Coronavirus From a Visitor to Haiti: Further Evidence of Transmission of Coronaviruses of Zoonotic Origin to Humans.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
75(1):e1184-e1187
[DOI] 10.1093/cid/ciab924.
[PMID] 34718467.
2021
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.
The New England journal of medicine.
384(9):795-807
[DOI] 10.1056/NEJMoa2031994.
[PMID] 33306283.
2021
Disseminated genitourinary histoplasmosis in a patient with AIDS with negative urine antigen testing.
BMJ case reports.
14(11)
[DOI] 10.1136/bcr-2021-243375.
[PMID] 34772673.
2021
Dissemination mechanisms of NDM genes in hospitalized patients.
JAC-antimicrobial resistance.
3(1)
[DOI] 10.1093/jacamr/dlab032.
[PMID] 34223104.
2021
Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial.
The Lancet. Respiratory medicine.
9(12):1365-1376
[DOI] 10.1016/S2213-2600(21)00384-2.
[PMID] 34672949.
2020
Evaluation of patient risk factors for infection with carbapenem-resistant Enterobacteriaceae.
American journal of infection control.
48(9):1028-1031
[DOI] 10.1016/j.ajic.2019.11.025.
[PMID] 31924388.
2020
Optimizing COVID-19 testing capabilities and clinical management using pathology informatics.
JAMIA open.
3(4):523-529
[DOI] 10.1093/jamiaopen/ooaa055.
[PMID] 33754137.
2020
Recovery of Curvularia mold from a duodenoscope after reprocessing in accordance with the manufacturer’s cleaning protocol.
American journal of infection control.
48(1):119-121
[DOI] 10.1016/j.ajic.2019.06.025.
[PMID] 31439371.
2020
The Clinical Presentation and Immunology of Viral Pneumonia and Implications for Management of Coronavirus Disease 2019.
Critical care explorations.
2(4)
[DOI] 10.1097/CCE.0000000000000109.
[PMID] 32426751.
2018
IKBKG (NEMO) 5′ Untranslated Splice Mutations Lead to Severe, Chronic Disseminated Mycobacterial Infections.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
67(3):456-459
[DOI] 10.1093/cid/ciy186.
[PMID] 29534156.
2018
Infectious Diseases Physicians: Leading the Way in Antimicrobial Stewardship.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
66(7):995-1003
[DOI] 10.1093/cid/cix1093.
[PMID] 29444247.
2017
Complete Genome Sequence of Dengue virus Type 2 from a Resident of North-Central Florida with Locally Transmitted Dengue Fever.
Genome announcements.
5(31)
[DOI] 10.1128/genomeA.00782-17.
[PMID] 28774993.
2016
Hemagglutinin Gene Clade 3C.2a Influenza A(H3N2) Viruses, Alachua County, Florida, USA, 2014-15.
Emerging infectious diseases.
22(1):121-3
[DOI] 10.3201/2201.151019.
[PMID] 26692074.
2016
Zika and Chikungunya virus co-infection in a traveller returning from Colombia, 2016: virus isolation and genetic analysis.
JMM case reports.
3(6)
[DOI] 10.1099/jmmcr.0.005072.
[PMID] 28348794.
2015
An outbreak of acute delirium from exposure to the synthetic cannabinoid AB-CHMINACA.
Clinical toxicology (Philadelphia, Pa.).
53(10):950-6
[DOI] 10.3109/15563650.2015.1100306.
[PMID] 26555732.
2015
Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum β-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae.
Antimicrobial agents and chemotherapy.
59(9):5793-7
[DOI] 10.1128/AAC.00548-15.
[PMID] 26169413.
2015
Severity of influenza A(H1N1) illness and emergence of D225G variant, 2013-14 influenza season, Florida, USA.
Emerging infectious diseases.
21(4):664-7
[DOI] 10.3201/eid2104.141375.
[PMID] 25811540.
2014
Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents.
Antimicrobial agents and chemotherapy.
58(8):4443-51
[DOI] 10.1128/AAC.00099-14.
[PMID] 24867988.
2014
Detection of Neisseria meningitidis from negative blood cultures and cerebrospinal fluid with the FilmArray blood culture identification panel.
Journal of clinical microbiology.
52(6):2262-4
[DOI] 10.1128/JCM.00352-14.
[PMID] 24740076.
2014
Enteric bacteria promote human and mouse norovirus infection of B cells.
Science (New York, N.Y.).
346(6210):755-9
[DOI] 10.1126/science.1257147.
[PMID] 25378626.
2014
High Percentage of False-Positive Results for Influenza B Obtained With a Rapid Influenza Point-Of-Care Test
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
59(4):605+-5
[DOI] 10.1093/cid/ciu315.
[PMID] 24795330.
2013
Log reduction of multidrug-resistant Gram-negative bacteria by the neutrophil-derived recombinant bactericidal/permeability-increasing protein.
International journal of antimicrobial agents.
42(6):571-4
[DOI] 10.1016/j.ijantimicag.2013.07.019.
[PMID] 24189329.
2013
Multi-functional analysis of Klebsiella pneumoniae fimbrial types in adherence and biofilm formation.
Virulence.
4(2):129-38
[DOI] 10.4161/viru.22974.
[PMID] 23302788.
2013
Resistance mechanisms in Campylobacter jejuni.
Virulence.
4(3):230-40
[DOI] 10.4161/viru.23753.
[PMID] 23406779.
2012
Antibacterial analysis of surgical adhesives.
Plastic and reconstructive surgery.
129(2):402e-404e
[DOI] 10.1097/PRS.0b013e31823af194.
[PMID] 22286489.
2011
Campylobacter capsule and lipooligosaccharide confer resistance to serum and cationic antimicrobials.
Virulence.
2(1):30-40
[PMID] 21266840.
2008
Reactive nitrogen species contribute to innate host defense against Campylobacter jejuni.
Infection and immunity.
76(3):986-93
[DOI] 10.1128/IAI.01063-07.
[PMID] 18174337.
2006
A paradigm for direct stress-induced mutation in prokaryotes.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
20(14):2476-85
[PMID] 17142797.
2004
Antibiotics in animal feed and spread of resistant Campylobacter from poultry to humans.
Emerging infectious diseases.
10(6):1158-9
[PMID] 15224671.
2004
Antimicrobial resistance in Campylobacter.
Emerging infectious diseases.
10(7)
[PMID] 15338553.
2002
The carboxyl-terminal domain of closely related endotoxin-binding proteins determines the target of protein-lipopolysaccharide complexes.
The Journal of biological chemistry.
277(10):7970-8
[PMID] 11773072.
1997
An opsonic function of the neutrophil bactericidal/permeability-increasing protein depends on both its N- and C-terminal domains.
Proceedings of the National Academy of Sciences of the United States of America.
94(20):10973-8
[PMID] 9380744.
1997
Lipopolysaccharide (LPS)-binding proteins BPI and LBP form different types of complexes with LPS.
The Journal of biological chemistry.
272(30):18682-5
[PMID] 9228038.
Grants
Jan 2025
– Jan 2025
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5245 for the Treatment of COVID-19 in Nonhospitalized Participants
Role: Principal Investigator
Funding: PPD INVESTIGATOR SERVICES LLC
via GILEAD SCIENCES
Jan 2025
ACTIVE
Utilizing phylodynamic and causal artificial intelligence methods for predicting and characterizing antibiotic resistant bacterial transmission within and beyond hospital settings
Role: Other
Funding: NATL INST OF HLTH NIAID
Jan 2024
ACTIVE
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAL02 ADMINISTERED INTRAVENOUSLY IN ADDITION TO STANDARD OF CARE IN SUBJECTS WITH SEVERE COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (SCABP)
Role: Principal Investigator
Funding: IQVIA Holdings
via EAGLE PHARMACEUTICALS
Nov 2023
ACTIVE
A Phase 2/3 Single-Arm, Open-label Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Obeldesivir in Pediatric Participants With COVID-19
Role: Principal Investigator
Funding: PPD INVESTIGATOR SERVICES LLC
via GILEAD SCIENCES
Sep 2022
ACTIVE
A Randomized, Placebo-Controlled, Double-Blinded Trial of the Safety and Efficacy of Tecovirimat for the Treatment of Human Monkeypox Virus Disease
Role: Principal Investigator
Funding: UNIV OF CALIFORNIA LOS ANGELES
via NATL INST OF HLTH NIAID
Jun 2022
ACTIVE
A Multicenter, Adaptive, Randomized, Blinded Controlled Trial Platform To Evaluate Safety and Efficacy of Strategies and Treatments for Hospitalized Patients with Respiratory Infections
Role: Principal Investigator
Funding: INST FOR CLINICAL RESEARCH
via NATL INST OF HLTH NIAID
Sep 2021
– Oct 2022
A Multicenter Platform Trial of Putative Therapeutics for the Treatment of COVID-19 in Hospitalized Adults
Role: Principal Investigator
Funding: LEIDOS
via NATL INST OF HLTH NCI
May 2021
– Jul 2024
Prevalence of Cefazolin Inoculum Effect in Mcthicillin Susceptible Staphylococcus aureus Bacteremia
Role: Co-Investigator
Funding: UF HEALTH SHANDS HOSPITAL
Mar 2021
– Mar 2024
ACTIV 4d RAAS
Role: Principal Investigator
Funding: VANDERBILT UNIVERSITY MEDICAL CENTER
via NATL INST OF HLTH NHLBI
Oct 2020
– Jun 2024
COVID-19: A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitals Adults with COVID-19
Role: Principal Investigator
Funding: NEW YORK UNIV
via NATL INST OF HLTH NHLBI
Mar 2020
– Aug 2021
A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults
Role: Principal Investigator
Funding: LEIDOS
via NATL INST OF HLTH NIAID
Sep 2016
– May 2018
Mucusal and Systemic Immunity, Vaccines and Microbiota Interplay in Humans
Role: Principal Investigator
Funding: UNIV OF MARYLAND COLLEGE PARK
via NATL INST OF HLTH NIAID
Education
Fellowship – Infectious Disease
2005
·
New York University
Residency – Internal Medicine
2002
·
New York University
Internship – Internal Medicine
2001
·
New York University
Medical Degree
2000
·
New York University
Doctor of Philosophy
1999
·
New York University
Bachelor of Arts – Biology
1992
·
City University of New York
Contact Details
Phones:
- Business:
- (352) 273-8606
Emails:
- Business:
- nicole.iovine@medicine.ufl.edu
Executive Assistant:
Addresses:
- Business Mailing:
-
PO Box 100289
GAINESVILLE FL 32610 - Business Street:
-
1600 SW Archer Road, D2-39
GAINESVILLE FL 32611